Valuation: Spyre Therapeutics, Inc.

Market Cap 8.79B 7.73B 7.18B 6.61B 12.39B 852B 12.61B 85.91B 33.51B 415B 33.01B 32.3B 1,441B P/E 2026 *
-32.5x
P/E 2027 * -29.6x
Enterprise Value 8.21B 7.22B 6.71B 6.17B 11.57B 795B 11.78B 80.24B 31.3B 388B 30.83B 30.17B 1,346B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.17%
Yield 2026 *
-
Yield 2027 * -
1 day+0.83%
1 week+6.24%
Current month+12.63%
1 month+3.03%
3 months+44.41%
6 months+212.13%
Current year+205.22%
1 week 97
Extreme 97
103.31
1 month 84.81
Extreme 84.81
105.09
Current year 28
Extreme 28
105.09
1 year 14.5
Extreme 14.505
105.09
3 years 8.43
Extreme 8.43
105.09
5 years 2.66
Extreme 2.66
212.5
10 years 2.66
Extreme 2.66
300
Manager TitleAgeSince
Chief Executive Officer 36 2023-11-26
Director of Finance/CFO 49 2023-08-31
Chief Tech/Sci/R&D Officer - 2023-11-26
Director TitleAgeSince
Director/Board Member 36 2023-11-26
Director/Board Member 39 2023-06-21
Director/Board Member 36 2023-06-21
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Fiscal year

Chief Financial Officer

22,500 0.0259%
7/1/26 Sell

Chief Executive Officer

-15,000 0.0173%
7/1/26 Fiscal year

Chief Technology Officer

25,002 0.0288%
Change 5-day change 1-year change 3-year change Capi.($)
+0.83%+6.24%+461.43%+574.24% 8.79B
+1.23%+0.35%+51.62%+87.98% 55.92B
+3.69%+9.92%+67.33%+72.60% 56.67B
+0.25%+0.55%-19.67%-15.22% 23.28B
+0.72%-0.05%+3.84%+409.54% 23.28B
-0.36%+5.73%+30.99%-3.58% 20.54B
-0.28%+1.39%+26.12%-29.66% 17.78B
-1.44%+5.67%+32.54%+544.11% 15.9B
-2.54%-8.73%+164.11%+289.45% 14.64B
+1.22%-0.05%+22.58%+182.63% 13.99B
Average +0.32%+1.76%+84.09%+211.21% 25.08B
Weighted average by Cap. +1.00%+3.28%+58.72%+151.94%

Financials

2026 *2027 *
Net sales - -
Net income -273M -240M -223M -205M -384M -26.4B -391M -2.66B -1.04B -12.87B -1.02B -1B -44.67B -311M -274M -254M -234M -439M -30.15B -447M -3.04B -1.19B -14.71B -1.17B -1.14B -51.02B
Net Debt -580M -510M -474M -436M -817M -56.14B -832M -5.66B -2.21B -27.38B -2.18B -2.13B -95B -485M -426M -396M -364M -683M -46.96B -696M -4.74B -1.85B -22.9B -1.82B -1.78B -79.46B
Logo Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD).
Employees
112
Date Price Change Volume
26-07-23 US$99.99 +0.83% 635,067
26-07-22 US$99.17 -3.44% 596,165
26-07-21 US$102.70 +5.52% 776,544
26-07-20 US$97.33 -2.89% 750,187
26-07-17 US$100.23 +6.49% 1,091,487
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
99.99USD
Average target price
103.93USD
Spread / Average Target
+3.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SYRE Stock